课题基金 / 基金详情

PRECLINICAL AND CLINICAL PHARMACOLOGY/EXPERIMENTAL THERAPEUTICS

PRECLINICAL AND CLINICAL PHARMACOLOGY/EXPERIMENTAL THERAPEUTICS
临床前和临床药理学/实验治疗
批准号:
5201335
负责人:
J GREM
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

J GREM的其他基金

相似基金

相关文献

中文摘要
翻译
通过长期输注给予氟尿嘧啶(FUra),或 由甲酰四氢叶酸调节的推注FUra导致20%-30%的应答率, 晚期结直肠癌患者是10-11个月。因此,创新 因此,迫切需要采取措施改善患者的预后。 结肠直肠癌和其他腺癌, 胃肠道我们正在采取几种办法。首先,我们 试图在临床试验中提高5-FU/亚叶酸的活性 通过加入其它调节剂 和γ,并降低GM-CSF的毒性和改变 FUra输注持续时间。我们也在研究其他的相互作用。 在实验室中使用FUra的药物,以确定最佳剂量 以及用于潜在临床用途的药物组合的序列。在 此外,我们认为,新的代理商与潜在的识别 抗胃肠道腺癌的活性是 至关重要我们对新药特别感兴趣, 显示出有效的体外活性(24小时暴露的IC 50小于或 等于10 μ M)和/或对人结肠直肠癌的体内功效 癌细胞系。旨在阐明最佳时间表的研究 此类药物的给药方式和作用机制对于 促进其合理的临床应用。我们一直对 实施I期临床试验,其中包括生物化学或 分子终点作为生物活性的反映, 特别代理人。我们的最终目标是开发新的代理商和药物 可用于治疗患有以下疾病的患者的组合: 胃肠道中出现的恶性肿瘤。这些治疗 这些策略也可以应用于治疗其他上皮性疾病, 实体瘤包括乳腺癌和头颈癌。
英文摘要
Administration of either fluorouracil (FUra) by protracted infusion or bolus FUra modulated by leucovorin results in response rates of 20%-30% in patients with advanced colorectal cancer is 10-11 months. thus, innovative strategies are crucially needed to improve the prognosis of patients with colorectal cancer and other adenocarcinomas arising in the gastrointestinal tract. We are taking several approaches. First, we are trying to improve the activity of 5-FU/leucovorin in clinical trials through the addition of other modulatory agents such as interferon alpha and gamma, and to reduce the toxicity with GM-CSF and alteration of the FUra infusion duration. We are also studying the interaction of other agents with FUra in the laboratory in an effort to define optimal doses and sequences of drug combinations for potential clinical use. In addition, we believe the identification of new agents with potential activity against adenocarcinomas of the gastrointestinal tract is of paramount importance. We are particularly interested in new drugs which display potent in vitro activity (IC50 for a 24 hour exposure less than or equal to 10 mu M) and/or in vivo efficacy against human colorectal carcinoma cell lines. Studies designed to elucidate the optimal schedule of administration and mechanism of action of such agents are vital to facilitate their rational clinical use. We have continuing interest in the implementation of Phase I clinical trials which incorporate biochemical or molecular endpoints as a reflection of the biologic activity of the particular agent. Our ultimate goal is to develop new agents and drug combinations which may be useful in the treatment of patients with malignancies arising in the gastrointestinal tract. These therapeutic strategies may also have application in the treatment of other epithelial solid tumors including breast cancer and head and neck cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PRECLINICAL AND CLINICAL PHARMACOLOGY/EXPERIMENTAL THERAPEUTICS
  • 批准号:
    3774662
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J GREM
  • 依托单位:
PRECLINICAL AND CLINICAL PHARMACOLOGY/EXPERIMENTAL THERAPEUTICS
  • 批准号:
    3838145
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J GREM
  • 依托单位:
PRECLINICAL AND CLINICAL PHARMACOLOGY/EXPERIMENTAL THERAPEUTICS
  • 批准号:
    3752408
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    J GREM
  • 依托单位:
PRECLINICAL AND CLINICAL PHARMACOLOGY/EXPERIMENTAL THERAPEUTICS
海外基金